Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Accumulated Expenses (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Other Accumulated Expenses for 12 consecutive years, with $30000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other Accumulated Expenses fell 88.89% year-over-year to $30000.0, compared with a TTM value of $30000.0 through Mar 2025, down 88.89%, and an annual FY2024 reading of $270000.0, up 513.64% over the prior year.
  • Other Accumulated Expenses was $30000.0 for Q1 2025 at Arcadia Biosciences, down from $270000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $298000.0 in Q4 2022 and bottomed at $30000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $184941.2, with a median of $264000.0 recorded in 2021.
  • The sharpest move saw Other Accumulated Expenses soared 513.64% in 2024, then crashed 88.89% in 2025.
  • Year by year, Other Accumulated Expenses stood at $162000.0 in 2021, then skyrocketed by 83.95% to $298000.0 in 2022, then crashed by 85.23% to $44000.0 in 2023, then skyrocketed by 513.64% to $270000.0 in 2024, then plummeted by 88.89% to $30000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for RKDA at $30000.0 in Q1 2025, $270000.0 in Q4 2024, and $30000.0 in Q3 2024.